Related Experiment Video
Updated: Mar 14, 2026
Anteromesial Temporal Lobectomy for Medically Intractable Temporal Lobe Epilepsy: An Operative Study
Published on: August 15, 2025
Pharmacological modulation in mesial temporal lobe epilepsy: Current status and future perspectives
Antonio Gambardella1, Angelo Labate1, Pierangelo Cifelli2
1Institute of Neurology, University Magna Græcia, Catanzaro, Italy; Institute of Molecular Bioimaging and Physiology of the National Research Council, Catanzaro, Italy.
Abstract:
Mesial temporal lobe epilepsy (MTLE) is frequently associated with hippocampal sclerosis (Hs), possibly caused by a primary brain injury that occurs a long time before the appearance of neurological symptoms. MTLE-Hs is, however, a heterogeneous condition that evolves with time, involving both environmental and genetic components. Recent experimental studies emphasize that drugs or drug combinations that target modulation and circuitry reorganization of the epileptogenic networks favorably modify the complex molecular and cellular alterations underlying MTLE. In particular, the link between neuroinflammation, GABAAR and epilepsy has been extensively studied mainly because of the relevant therapeutic implications that the pharmacological modulation of these phenomena would have in the clinical practice. In this review, we briefly summarize the studies that could pave the road to develop new disease-modifying therapeutic strategies for pharmacoresistant MTLE patients. Both clinical observations in human MTLE and experimental findings will be discussed, highlighting the potential modulatory crosstalk between the deregulation of the inhibitory (GABAergic) transmission and the sustained activation of the innate immune response.
Insights
Mesial temporal lobe epilepsy (MTLE) with hippocampal sclerosis involves complex genetic and environmental factors. Targeting neuroinflammation and GABAergic transmission may offer new therapeutic strategies for drug-resistant epilepsy.
Area of Science:
- Neuroscience
- Epileptology
- Immunology
Background:
- Mesial temporal lobe epilepsy (MTLE) often co-occurs with hippocampal sclerosis (Hs).
- MTLE-Hs is a dynamic condition influenced by genetic and environmental factors.
- Underlying brain injury may precede epilepsy onset by years.
Purpose of the Study:
- To review current research on disease-modifying strategies for pharmacoresistant MTLE.
- To explore the interplay between neuroinflammation and GABAergic transmission in MTLE.
- To highlight potential therapeutic targets for MTLE-Hs.
Main Methods:
- Review of clinical observations in human MTLE patients.
- Analysis of experimental findings from preclinical studies.
- Focus on molecular and cellular alterations in epileptogenic networks.
Main Results:
- Neuroinflammation and GABAergic system dysfunction are key features of MTLE.
- Modulation of epileptogenic networks shows therapeutic potential.
- Crosstalk between immune response and inhibitory neurotransmission is evident.
Conclusions:
- Pharmacological targeting of neuroinflammation and GABAAR modulation offers promising avenues for treating drug-resistant MTLE.
- Understanding the complex molecular pathways is crucial for developing novel disease-modifying therapies.
- Combined therapeutic strategies may be necessary for effective MTLE management.
More Related Videos
Related Concept Videos
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:14Antiepileptic Drugs: Glutamate Antagonists
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
01:08Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
01:17Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...